BioCentury | Jan 6, 2017
Company News

Mercachem, Almirall deal

...Mercachem granted Almirall exclusive rights to cytokine blockers program to treat inflammatory skin diseases. Mercachem will...
...inquiries. Mercachem B.V. , Nijmegen, the Netherlands Almirall S.A. (Madrid:ALM), Barcelona, Spain Business: Inflammation, Dermatology Chris Lieu Almirall S.A. Mercachem B.V....
BioCentury | May 20, 2013
Company News

Mercachem B.V., ProQinase cancer news

...CROs ProQinase and Mercachem received a €2.5 million ($3.3 million) grant from the EU's Eurostars program...
...partners will develop biochemical, cell-based and in vivo test systems, along with scaffold-based compound libraries. Mercachem B.V....
BioCentury | Feb 25, 2013
Company News

Edelris, Sygnature Discovery, Syncom B.V., Taros Chemicals GmbH & Co. KG, AstraZeneca, Bayer, Lundbeck, J&J, Mercachem B.V., Merck KGaA, Sanofi, Innovative Medi

...medium-sized enterprises (SMEs) will contribute about 200,000 compounds. The participating SMEs include Sygnature, Syncom, Edelris, Mercachem...
...Leverkusen, Germany H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Mercachem B.V....
BioCentury | Mar 26, 2012
Company News

Dr. August Wolff Arzneimittel GmbH & Co. KG, Merachem deal

...CRO Merachem said the companies reached in vivo proof-of-concept in two programs to develop compounds with...
...Details were not disclosed. Dr. August Wolff Arzneimittel GmbH & Co. KG , Bielefeld, Germany Merachem...
BioCentury | Aug 24, 2009
Company News

IOTA Pharmaceuticals Ltd., Mercachem B.V., Nycomed Group A/S, Drugs for Neglected Diseases initiative, Royal Tropical Institute, TI Pharma, University of Bern,

...million) over four years. Further terms were not disclosed. IOTA Pharmaceuticals Ltd. , Cambridge, U.K. Mercachem B.V....
Items per page:
1 - 5 of 5
BioCentury | Jan 6, 2017
Company News

Mercachem, Almirall deal

...Mercachem granted Almirall exclusive rights to cytokine blockers program to treat inflammatory skin diseases. Mercachem will...
...inquiries. Mercachem B.V. , Nijmegen, the Netherlands Almirall S.A. (Madrid:ALM), Barcelona, Spain Business: Inflammation, Dermatology Chris Lieu Almirall S.A. Mercachem B.V....
BioCentury | May 20, 2013
Company News

Mercachem B.V., ProQinase cancer news

...CROs ProQinase and Mercachem received a €2.5 million ($3.3 million) grant from the EU's Eurostars program...
...partners will develop biochemical, cell-based and in vivo test systems, along with scaffold-based compound libraries. Mercachem B.V....
BioCentury | Feb 25, 2013
Company News

Edelris, Sygnature Discovery, Syncom B.V., Taros Chemicals GmbH & Co. KG, AstraZeneca, Bayer, Lundbeck, J&J, Mercachem B.V., Merck KGaA, Sanofi, Innovative Medi

...medium-sized enterprises (SMEs) will contribute about 200,000 compounds. The participating SMEs include Sygnature, Syncom, Edelris, Mercachem...
...Leverkusen, Germany H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Mercachem B.V....
BioCentury | Mar 26, 2012
Company News

Dr. August Wolff Arzneimittel GmbH & Co. KG, Merachem deal

...CRO Merachem said the companies reached in vivo proof-of-concept in two programs to develop compounds with...
...Details were not disclosed. Dr. August Wolff Arzneimittel GmbH & Co. KG , Bielefeld, Germany Merachem...
BioCentury | Aug 24, 2009
Company News

IOTA Pharmaceuticals Ltd., Mercachem B.V., Nycomed Group A/S, Drugs for Neglected Diseases initiative, Royal Tropical Institute, TI Pharma, University of Bern,

...million) over four years. Further terms were not disclosed. IOTA Pharmaceuticals Ltd. , Cambridge, U.K. Mercachem B.V....
Items per page:
1 - 5 of 5